Montes Archimedes Acquisition (ROIV)
(Delayed Data from NSDQ)
$11.68 USD
+0.13 (1.13%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $11.70 +0.02 (0.17%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.68 USD
+0.13 (1.13%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $11.70 +0.02 (0.17%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
Zacks News
Roivant (ROIV), Pfizer Form Vant for Inflammatory Disease Drug
by Zacks Equity Research
Roivant Sciences (ROIV), Pfizer's (PFE) new Vant company will take care of funding the global development of RVT-3101 in inflammatory and fibrotic diseases.
Pharma Stock Roundup: PFE & AZN Ink New M&A Deals, LLY Meets Alzheimer's Study Goal
by Kinjel Shah
Pfizer (PFE) and Roivant Sciences (ROIV) form a new Roivant subsidiary to develop an inflammatory disease drug. AstraZeneca (AZN) to boost cell therapies portfolio with private company buyout.
Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Roivant Sciences Ltd. (ROIV) delivered earnings and revenue surprises of -2.44% and 86.73%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Atyr Pharma (LIFE) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Atyr Pharma (LIFE) delivered earnings and revenue surprises of -2.22% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Roivant Sciences Ltd. (ROIV) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Roivant Sciences Ltd. (ROIV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioAtla, Inc. (BCAB) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
BioAtla, Inc. (BCAB) delivered earnings and revenue surprises of 10.39% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Geron (GERN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Geron (GERN) delivered earnings and revenue surprises of -11.11% and 156.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 14.29% and 83.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Roivant Sciences Ltd. (ROIV) Soars 5.8: Is Further Upside Left in the Stock?
by Zacks Equity Research
Roivant Sciences Ltd. (ROIV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Roivant Sciences Ltd. (ROIV) delivered earnings and revenue surprises of -60% and 33.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Venus Concept (VERO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Venus Concept (VERO) delivered earnings and revenue surprises of -100% and 9.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Synlogic, Inc. (SYBX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 4.35% and 49.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Exelixis (EXEL) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of 10% and 7.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Global Blood (GBT): Can Its 41.4% Jump Turn into More Strength?
by Zacks Equity Research
Global Blood (GBT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of 77.88% and 2,483.28%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Pfizer (PFE) Discloses Autoimmune Drug Deal With Priovant
by Zacks Equity Research
Pfizer (PFE) announces the name of the new company that it formed with its partner, Roivant Sciences (ROIV), to develop and market its dual TYK2/JAK1 inhibitor.
Here's What to Expect Ahead of BlackBerry's (BB) Q1 Earnings
by Zacks Equity Research
BlackBerry's (BB) first-quarter fiscal 2023 revenues are likely to have benefited from its billings growth and higher demand for IoT and cyber security solutions.